/CNW/ - Verify Diagnostics announced today that Health Canada has authorized the Assure Tech Ecotest COVID-19 serological rapid test to be used at the.
Study design and results:
Both the experimental and the control groups were inoculated with human colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham control were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Previously published interim results showing a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p value ≤ 0.022. The study was concluded after 16 days of treatment (day 21) when a member of the control group reached a predetermined tumor size. Final results recorded a significant and robust
33% reduction in tumor volume in RCC-33 treated mice in comparison with the control group, p value ≤0.016.
Share this article
Share this article
WILMINGTON, Del., Jan. 15, 2021 /PRNewswire/ The Center for the Biology of Chronic Disease (CBCD) announces an important discovery on the cause of Parkinson s diseases. The discovery shows how many common latent viruses, which infect the central and peripheral nervous systems, can cause Parkinson s disease (1). Latent viruses are hidden in the body in a way that most individuals don t know that they are infected. The discovery was published in the
Journal of NeuroVirology. More details are available at: https://pubmed.ncbi.nlm.nih.gov/33405201/.
Microcompetition Model: Book
The discovery was made possible by using the microcompetition model. The model uncovered new relationships between seemingly unrelated observations reported in the scientific literature. The discovery describes the molecular steps that lead from a latent infection to the clinical symptoms of Parkinson s disease. Many common viruses can cause the disease.
Share this article
GOTHENBURG, Sweden, Jan. 15, 2021 /PRNewswire/
Isofol Medical AB (publ) ( Isofol ), (Nasdaq First North Premier Growth Market: ISOFOL) announces that a poster presentation is presented today at ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene expression of the folate pathway in patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy in combination with arfolitixorin. Furthermore, Isofol gives an update of the timing of the interim analysis in the global Phase III AGENT study.
In connection to ASCO-GI, Isofol together with QuartzBio, the Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, will present a poster with the title Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy on asco.org between 2.00 PM -